Table of Contents
International Journal of Medical Genetics
Volume 2014, Article ID 180270, 6 pages
http://dx.doi.org/10.1155/2014/180270
Review Article

The Role of Transforming Growth Factor-Beta in Diabetic Nephropathy

1Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, MG, Brazil
2Faculdade de Farmácia, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, MG, Brazil
3Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos 6627, Pampulha, 31270-901 Belo Horizonte, MG, Brazil

Received 5 October 2013; Revised 16 November 2013; Accepted 4 December 2013; Published 28 January 2014

Academic Editor: George N. Goulielmos

Copyright © 2014 Karina Braga Gomes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. F. Navarro and C. Mora, “Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy,” TheScientificWorldJOURNAL, vol. 6, pp. 908–917, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. J. F. Navarro-González and C. Mora-Fernández, “The role of inflammatory cytokines in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 19, no. 3, pp. 433–442, 2008. View at Publisher · View at Google Scholar
  3. S. M. El-Sherbini, S. M. Shahen, Y. M. Mosaad, M. S. Abdelgawad, and R. M. Talaat, “Gene polymorphism of transforming growth factor-β1 in Egyptian patients with type 2 diabetes and diabetic nephropathy,” Acta Biochimica et Biophysica Sinica, vol. 45, no. 4, pp. 330–338, 2013. View at Publisher · View at Google Scholar
  4. J. C. Pickup, G. C. Chusney, S. M. Thomas, and D. Burt, “Is type II diabetes mellitus a disease of the innate immune system?” Life Sciences, vol. 67, no. 3, pp. 291–300, 2000. View at Publisher · View at Google Scholar
  5. C. Herder, E. J. Brunner, W. Rathmann et al., “Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study,” Diabetes Care, vol. 32, no. 3, pp. 421–423, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Manabe, “Chronic inflammation links cardiovascular, metabolic and renal diseases,” Circulation Journal, vol. 75, no. 12, pp. 2739–2748, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. C. C. Wu, H. K. Sytwu, and Y. F. Lin, “Cytokines in diabetic nephropathy,” Advances in Clinical Chemistry, vol. 56, pp. 55–74, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. R. B. Goldberg, “Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 9, pp. 3171–3182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Matsumoto, Y. Sera, Y. Ueki, G. Inukai, E. Niiro, and S. Miyake, “Comparison of serum concentrations of soluble adhesion molecules in diabetic microangiopathy and macroangiopathy,” Diabetic Medicine, vol. 19, no. 10, pp. 822–826, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. M. F. Lopes-Virella, R. E. Carter, G. E. Gilbert et al., “Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications,” Diabetes Care, vol. 31, no. 10, pp. 2006–2012, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. A. S. Astrup, L. Tarnow, L. Pietraszek et al., “Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate,” Diabetes Care, vol. 31, no. 6, pp. 1170–1176, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Heldin, M. Landström, and A. Moustakas, “Mechanism of TGF-β signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition,” Current Opinion in Cell Biology, vol. 21, no. 2, pp. 166–176, 2009. View at Publisher · View at Google Scholar
  13. J. Massagué and D. Wotton, “Transcriptional control by the TGF-β/Smad signaling system,” EMBO Journal, vol. 19, no. 8, pp. 1745–1754, 2000. View at Google Scholar · View at Scopus
  14. W. Wang, V. Koka, and H. Y. Lan, “Transforming growth factor-β and Smad signalling in kidney diseases,” Nephrology, vol. 10, no. 1, pp. 48–56, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Qian, E. Feldman, S. Pennathur, M. Kretzler, and F. C. Brosius, “From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy,” Diabetes, vol. 57, no. 6, pp. 1439–1445, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Yamamoto, T. Nakamura, N. A. Noble, E. Ruoslahti, and W. A. Border, “Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 5, pp. 1814–1818, 1993. View at Google Scholar · View at Scopus
  17. Y. Qian, E. Feldman, S. Pennathur, M. Kretzler, and F. C. Brosius, “From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy,” Diabetes, vol. 57, no. 6, pp. 1439–1445, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Sharma and F. N. Ziyadeh, “Hyperglycemia and diabetic kidney disease: the case for transforming growth factor-β as a key mediator,” Diabetes, vol. 44, no. 10, pp. 1139–1146, 1995. View at Google Scholar · View at Scopus
  19. W. A. Border, N. A. Noble, T. Yamamoto et al., “Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease,” Nature, vol. 360, no. 6402, pp. 361–364, 1992. View at Publisher · View at Google Scholar · View at Scopus
  20. E. W. R. Rivarola, M. Moyses-Neto, M. Dantas, C. G. Da-Silva, R. Volpini, and T. M. Coimbra, “Transforming growth factor β activity in urine of patients with type 2 diabetes and diabetic nephropathy,” Brazilian Journal of Medical and Biological Research, vol. 32, no. 12, pp. 1525–1528, 1999. View at Google Scholar · View at Scopus
  21. D. Mucida, Y. Park, G. Kim et al., “Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid,” Science, vol. 317, no. 5835, pp. 256–260, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Veldhoen, R. J. Hocking, C. J. Atkins, R. M. Locksley, and B. Stockinger, “TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells,” Immunity, vol. 24, no. 2, pp. 179–189, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Okamoto, Y. Iwai, M. Oh-Hora et al., “IκBζ regulates TH 17 development by cooperating with ROR nuclear receptors,” Nature, vol. 464, no. 7293, pp. 1381–1385, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. W. A. Border, S. Okuda, L. R. Languino, M. B. Sporn, and E. Ruoslahti, “Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1,” Nature, vol. 346, no. 6282, pp. 371–374, 1990. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Isaka, Y. Fujiwara, N. Ueda, Y. Kaneda, T. Kamada, and E. Imai, “Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene into the rat kidney,” Journal of Clinical Investigation, vol. 92, no. 6, pp. 2597–2601, 1993. View at Google Scholar · View at Scopus
  26. Z. I. Niemir, H. Stein, I. L. Noronha et al., “PDGF and TGF-β contribute to the natural course of human IgA glomerulonephritis,” Kidney International, vol. 48, no. 5, pp. 1530–1541, 1995. View at Google Scholar · View at Scopus
  27. N. Perico and G. Remuzzi, “Inhibition of TGF-β expression: a novel role for thiazolidinediones to implement renoprotection in diabetes,” Kidney International, vol. 72, no. 12, pp. 1419–1421, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Ohtomo, Y. Izuhara, S. Takizawa et al., “Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model,” Kidney International, vol. 72, no. 12, pp. 1512–1519, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Ohga, K. Shikata, K. Yozai et al., “Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-κB activation,” The American Journal of Physiology—Renal Physiology, vol. 292, no. 4, pp. F1141–F1150, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. D. A. Lawrence, “Transforming growth factor-β: an overview,” Kidney International Supplements, no. 49, pp. S19–S23, 1995. View at Google Scholar · View at Scopus
  31. Y. Watanabe, A. Kinoshita, T. Yamada et al., “A catalog of 106 single-nucleotide polymorphisms (SNPs) and 11 other types of variations in genes for transforming growth factor-β1 (TGF-β1) and its signaling pathway,” Journal of Human Genetics, vol. 47, no. 9, pp. 478–483, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Derynck, L. Rhee, E. Y. Chen, and A. van Tilburg, “Intron-exon structure of the human transforming growth factor-β precursor gene,” Nucleic Acids Research, vol. 15, no. 7, pp. 3188–3189, 1987. View at Google Scholar · View at Scopus
  33. T. S. Ahluwalia, M. Khullar, M. Ahuja et al., “Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians,” PLoS ONE, vol. 4, no. 4, Article ID e5168, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Buraczynska, I. Baranowicz-Gaszczyk, E. Borowicz, and A. Ksiazek, “TGF-β1 and TSC-22 gene polymorphisms and susceptibility to microvascular complications in type 2 diabetes,” Nephron—Physiology, vol. 106, no. 4, pp. p69–p75, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Akai, H. Sato, H. Ozaki, M. Iwano, Y. Dohi, and M. Kanauchi, “Association of transforming growth factor-β1 T29C polymorphism with the progression of diabetic nephropathy,” The American Journal of Kidney Diseases, vol. 38, no. 4, pp. S182–S185, 2001. View at Google Scholar · View at Scopus
  36. T. Y. H. Wong, P. Poon, K. M. Chow, C. C. Szeto, M. K. Cheung, and P. K. T. Li, “Association of transforming growth factor-β (TGF-β) T869C (Leu 10Pro) gene polymorphisms with type 2 diabetic nephropathy in Chinese,” Kidney International, vol. 63, no. 5, pp. 1831–1835, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Buraczynska, I. Baranowicz-Gaszczyk, E. Borowicz, and A. Ksiazek, “TGF-β1 and TSC-22 gene polymorphisms and susceptibility to microvascular complications in type 2 diabetes,” Nephron—Physiology, vol. 106, no. 4, pp. p69–p75, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. X. Mou, W. H. Liu, D. Y. Zhou et al., “Association of Chinese medicine constitution susceptibility to diabetic nephropathy and transforming growth factor-β1 (T869C) gene polymorphism,” Chinese Journal of Integrative Medicine, vol. 17, no. 9, pp. 680–684, 2011. View at Google Scholar · View at Scopus
  39. N. Babel, L. Gabdrakhmanova, M. H. Hammer et al., “Predictive value of cytokine gene polymorphisms for the development of end-stage renal disease,” Journal of Nephrology, vol. 19, no. 6, pp. 802–807, 2006. View at Google Scholar · View at Scopus
  40. A. Valladares-Salgado, J. Angeles-MartÍnez, M. Rosas et al., “Association of polymorphisms within the transforming growth factor-β1 gene with diabetic nephropathy and serum cholesterol and triglyceride concentrations,” Nephrology, vol. 15, no. 6, pp. 644–648, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Minami, N. Kume, H. Kataoka et al., “Transforming growth factor-β1 increases the expression of lectin-like oxidized low-density lipoprotein receptor-1,” Biochemical and Biophysical Research Communications, vol. 272, no. 2, pp. 357–361, 2000. View at Publisher · View at Google Scholar · View at Scopus
  42. X. Zhou, T. P. Johnston, D. Johansson et al., “Hypercholesterolemia leads to elevated TGF-β1 activity and T helper 3-dependent autoimmune responses in atherosclerotic mice,” Atherosclerosis, vol. 204, no. 2, pp. 381–387, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. T. S. Ahluwalia, M. Khullar, M. Ahuja et al., “Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians,” PLoS ONE, vol. 4, no. 4, Article ID e5168, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Prasad, A. K. Tiwari, K. M. P. Kumar et al., “Association of TGFβ1, TNFα, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians,” BMC Medical Genetics, vol. 8, article 20, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Jia, L. Yu, B. Gao, and Q. Ji, “Association between the T869C polymorphism of transforming growth factor-β 1 and diabetic nephropathy: a meta-analysis,” Endocrine, vol. 40, no. 3, pp. 372–378, 2011. View at Google Scholar · View at Scopus
  46. M. Murphy, F. Hickey, and C. Godson, “IHG-1 amplifies TGF-β1 signalling and mitochondrial biogenesis and is increased in diabetic kidney disease,” Current Opinion in Nephrology and Hypertension, vol. 22, no. 1, pp. 77–84, 2013. View at Publisher · View at Google Scholar
  47. X. Cheng, W. Gao, Y. Dang et al., “Both ERK/MAPK and TGF-β/Smad signaling pathways play a role in the kidney fibrosis of diabetic mice accelerated by blood glucose fluctuation,” Journal of Diabetes Research, vol. 2013, Article ID 463740, 8 pages, 2013. View at Publisher · View at Google Scholar